Ramucirumab Plus Folfiri Or Irinotecan As Second-Line Therapy In Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma

JOURNAL OF GASTROINTESTINAL ONCOLOGY(2021)

引用 1|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要